Vaping News

NRT? No Thanks!

Latest research shows that traditional NRT products are failing to enthuse smokers attempting to quit.

Share on:
According to a study conducted by researchers in Denmark, approved nicotine replacement products are filling quitters with a sense of disquiet. This can’t be good news for Pharma, feeling the continuing squeeze from electronic cigarettes.

In The Cult of Pharmacology by Richard DeGrandpre, he mentions how “there was a huge surge of optimism” when nicotine patches were developed in the early 90s. But since their introduction they’ve only managed to help 17.7% of smokers to leave the weed behind.

The Danish team looked at the attitudes towards NRT from long-term, heavy users of nicotine. The participants were all long-term users of NRT, over 12 months, and were asked for their reasons for and level of happiness with continuing to use it.

88% of the subjects stated that they objected to the costs of NRT, were tired of feeling addicted to them and held strong concerns over the long-term health implications of NRT product use. 77.3% were moderate to high-level users of nicotine.

The team concluded that a significant majority of users would like to quit NRT products and suggest that the solution may be to improve the quality of counselling they receive.

The success of electronic cigarettes was not factored into the study – but is playing a large part in strategic planning at GlaxoSmithKline. Rapid growth in ecig adoption has left a large hole in sales of the British firm’s patches and gum.

Speaking to Reuters, Chief Executive Andrew Witty said: “he and his team had spent ‘a few days’ exploring whether they should compete directly by becoming an e-cigarette maker, but had swiftly decided against it.”

“Of course, it's definitely taken a bit of our market, no question at all -- but there's a lot of competition in that space anyway.”

GlaxoSmithKline are the company responsible for the Nicorette and NicoDerm CQ brands, and the increasingly questioned Zyban. One of its strategies for combatting declining sales is the forming of a joint venture with Novartis, the manufacturer of Nicotinell.

“E-cigarettes are just too controversial for GSK to want to get involved in at this stage. There's not enough data to provide robust evidence of the products' risks and benefits,” Witty added.

In 2014, research found that smokers switching to e-cigarettes are far more likely to succeed in quitting or cutting down than users of traditional NRT products.

 

Dave Cross avatar

Dave Cross

Journalist at POTV
View Articles

Dave is a freelance writer; with articles on music, motorbikes, football, pop-science, vaping and tobacco harm reduction in Sounds, Melody Maker, UBG, AWoL, Bike, When Saturday Comes, Vape News Magazine, and syndicated across the Johnston Press group. He was published in an anthology of “Greatest Football Writing”, but still believes this was a mistake. Dave contributes sketches to comedy shows and used to co-host a radio sketch show. He’s worked with numerous vape companies to develop content for their websites.

Join the discussion

Vaping News

Harm Reduction For The Rich

The United Kingdom risks becoming a harm reduction country only for the wealthy, according to Michael Landl of the World Vapers’ Alliance

Vaping News

Sacrificing Health For 2p Cut

Tory Government alienates vaping voters with its mission to cut tax by an unaffordable 2p to attract voters by placing a tax on vape products in the forthcoming budget

Vaping News

Scotland Announces Single-Use Vape Action

A ban on the sale and supply of single-use vapes in Scotland is due to come into effect on 1 April 2025, under proposed legislation published today

Vaping News

Industry Licensing Scheme Proposed

A vape industry licensing scheme will generate £50m+ per year to combat underage and illicit vape sales according to industry experts